Topics

Dose-escalation Study of Oral Administration of LP-108 in Patients With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

2019-10-30 14:03:46 | BioPortfolio

Summary

A Phase 1, Multi-center, Open-label, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 in Subjects with Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Description

The primary objectives are to assess the safety and tolerability profile, determine the maximum tolerated dose (MTD), and/or the recommended Phase 2 dose (RP2D) of LP-108 administered daily as a single agent dosed orally in adult subjects with relapsed/refractory MDS/CMML/AML; to characterize the pharmacokinetics (PK) profile of LP-108 in adult subjects with relapsed/refractory MDS/CMML/AML.

Secondary objectives are to evaluate preliminary efficacy regarding the effect of LP-108 (monotherapy or combination therapy) on objective response rate (ORR) for AML (including rate of complete remission [CR]with or without minimal residual disease [MRD], CR with incomplete platelet recovery [CRp], CR with incomplete blood count recovery [CRi], morphologic leukemia-free state (MLFS), and partial remission [PR]), and ORR for MDS (CR with or without persistent dysplasia, PR, and marrow CR), and ORR for CMML (including CR, complete cytogenetic remission, PR, marrow response, and clinical benefit), progression-free survival (PFS), duration of response (DOR) (for all subjects achieving an objective response), event-free survival (EFS), and overall survival (OS) for AML, MDS and CMML.

Exploratory objectives are to explore blood borne biomarkers that may influence development of hematological malignancy and/or response to treatment (where response is defined broadly to include efficacy, tolerability, or safety); to study genes/genetic variation that may influence PK or response (ie, absorption, distribution, metabolism, excretion, safety, tolerability, and efficacy) to treatment, and/or genetic drivers of hematological malignancy such as AML, MDS, and CMML; to explore the relationship between PK and selected endpoints (ie, blood borne biomarkers), where deemed appropriate.

Once the MTD is declared and the RP2D is established, additional subjects will be enrolled in a cohort expansion phase (Phase 1b) that might adapt combination therapies with other agents such as hypomethylating agents (HMA), and in the United States and ex-US sites.

Study Design

Conditions

AML/MDS

Intervention

LP-108

Location

H. Lee Moffitt Cancer Center Research Institute
Tampa
Florida
United States
33612

Status

Not yet recruiting

Source

Newave Pharmaceutical Inc

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-10-30T14:03:46-0400

Clinical Trials [195909 Results]

The Utility of Peri-operative Arnica Montana for Reduction of Ecchymosis in Rhinoplasty Surgery

Arnica montana is a homeopathic drug that is made in accordance with the official methods of the Homeopathic Pharmacopoeia of the United States (HPUS) and is commonly used by cosmetic surg...

Pharyngeal Size in Patients With Obstructive Tonsils Under Orthodontic Treatment

Enlarged tonsils and malocclusion has relationship with sleep disturbance in children. The consequences of these features can include aggravation of craniofacial growth such that the devel...

The Biology of Chronic Preconditioning: Genomic and Physiologic Mechanisms of Response

The purpose of this study is to assess the effects of repeated RIPC and exercise, on exercise performance, skeletal muscle responses and circulating cellular and humoral biology in humans

Pilot Study of Raltegravir Lipodystrophy IISP

The substitution of raltegravir for the NRTIs will result in some reversal of the long term adverse effect of lipodystrophy (specifically peripheral lipoatrophy) that is associated with th...

Esophagoscopy in Evaluating Treatment in Patients With Stage I-IV Head and Neck Cancer Who Are Undergoing Radiation Therapy and/or Chemotherapy

Brief Summary: RATIONALE: Comparing results of diagnostic procedures, such as esophagoscopy, done before and after radiation therapy and/or chemotherapy may help doctors predict a patient...

PubMed Articles [1008913 Results]

Evaluation of the self-directed format of Walk With Ease in patients with systemic lupus erythematosus: the Walk-SLE Pilot Study.

To conduct a proof-of-concept pilot evaluation of the self-directed format of Walk With Ease (WWE), a 6-week walking program developed for adults with arthritis, in patients with systemic lupus erythe...

A systemic lupus erythematosus patient with thunderclap headache: reversible cerebral vasoconstriction syndrome.

Headaches are common in patients with systemic lupus erythematosus (SLE). It is important to identify the exact cause of headaches in SLE to avoid unnecessary steroid or immunosuppressive therapy like...

Editorial Comment.

Editorial Comment.

Editorial Comment.

Medical and Biotech [MESH] Definitions

An ionophorous, polyether antibiotic from Streptomyces chartreusensis. It binds and transports cations across membranes and uncouples oxidative phosphorylation while inhibiting ATPase of rat liver mitochondria. The substance is used mostly as a biochemical tool to study the role of divalent cations in various biological systems.

An organothiophosphate insecticide.

Places where animals are slaughtered and dressed for market.

Shortened forms of written words or phrases used for brevity.

That portion of the body that lies between the THORAX and the PELVIS.

More From BioPortfolio on "Dose-escalation Study of Oral Administration of LP-108 in Patients With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)"

Quick Search

Relevant Topic

Leukemia
Leukemia is a type of cancer of the blood or bone marrow characterized by an abnormal increase of immature white blood cells called "blasts". Leukemia is a broad term covering a spectrum of diseases. In turn, it is part of the even broader grou...


Searches Linking to this Trial